Table 3.
Functional parameters of jejunal PCCs in response to 5-HT3 and/or 5-HT4 antagonists
| A. Granisetron, 1 μm | ||||
|---|---|---|---|---|
| Balb/c (n = 8) |
C57Bl/6 (n = 9) |
|||
| Jejunum Treatment: | Control | Granisetron | Control | Granisetron |
| Frequency (min−1) | 0.71 ± 0.1 | 0.56 ± 0.1 | 0.56 ± 0.1 | 0.33 ± 0.1* |
| Amplitude (%) | 9 ± 2 | 8 ± 1 | 12 ± 2 | 7 ± 2* |
| Duration (s) | 53.9 ± 3.5 | 56.8 ± 4.9 | 61.2 ± 6.0 | 57.5 ± 7.4 |
| Quiescence (Q, s) | 35.2 ± 10.8 | 44.0 ± 7.8 | 56.2 ± 14.4 | 315.3 ± 128.1 |
| Period (I, s) | 88.9 ± 13.1 | 101.1 ± 11.9 | 119.4 ± 16.7 | 373.1 ± 122.1 |
| Inhibition ratio (Q/I) | 0.33 ± 0.1 | 0.55 ± 0.1 | 0.42 ± 0.1 | 0.55 ± 0.1 |
| Contractions/PCC | 9.0 ± 1.0 | 9.3 ± 1.2 | 9.0 ± 0.9 | 10.5 ± 1.8 |
| Speed (mm s−1) | 1.5 ± 0.3 | 1.8 ± 0.8 | 3.3 ± 0.7 | 2.6 ± 0.7 |
| Velocity (mm s−1) | −0.5 ± 0.9 | −0.4 ± 0.2 | 0.3 ± 0.9 | 1.9 ± 0.2 |
| B. SB207266, 10 nm | ||||
| Balb/c (n = 6) | C57Bl/6 (n = 8) | |||
| Jejunum Treatment: | Control | SB207266 | Control | SB207266 |
| Frequency (min−1) | 0.51 ± 0.04 | 0.38 ± 0.1 | 0.31 ± 0.04 | 0.28 ± 0.04 |
| Amplitude (%) | 10 ± 2 | 6 ± 2 | 13 ± 5 | 13 ± 4 |
| Duration (s) | 45.8 ± 10.6 | 51.4 ± 12.6 | 109.5 ± 22.7 | 73.6 ± 6.3 |
| Quiescence (Q, s) | 43.8 ± 10.8 | 259.5 ± 188.9 | 85.1 ± 15.2 | 113.2 ± 15.5 |
| Period (I, s) | 90.0 ± 18.8 | 310.0 ± 178.9 | 194.8 ± 25.0 | 187.2 ± 15.7 |
| Inhibition ratio (Q/I) | 0.44 ± 0.1 | 0.6 ± 0.1 | 0.44 ± 0.1 | 0.59 ± 0.1* |
| Contractions/PCC | 10.4 ± 3.3 | 11.6 ± 2.5 | 25.8 ± 3.2 | 17.8 ± 2.5 |
| Speed (mm s−1) | 1.6 ± 0.6 | 1.2 ± 0.4 | 1.4 ± 0.2 | 2.5 ± 0.5 |
| Velocity (mm s−1) | −0.8 ± 0.3 | 0.2 ± 0.4 | −0.5 ± 0.5 | 0.03 ± 1.0 |
| C. Combined antagonists | ||||
| Balb/c (n = 6) | C57Bl/6 (n = 10) | |||
| Jejunum Treatment: | Control | Combined antagonists | Control | Combined antagonists |
| Frequency (min−1) | 0.50 ± 0.1 | 0.39 ± 0.1 | 0.46 ± 0.1 | 0.09 ± 0.05† |
| Amplitude (%) | 20 ± 5 | 14 ± 4 | 12 ± 2 | 4 ± 2* |
| Duration (s) | 77.3 ± 16.2 | 78.3 ± 33.4 | 77.7 ± 6.6 | 19.0 ± 9.9† |
| Quiescence (Q, s) | 65.9 ± 17.6 | 230.5 ± 194.2 | 47.6 ± 9.4 | 862.3 ± 172.0† |
| Period (I, s) | 142.1 ± 30.0 | 315.9 ± 181.4 | 125.1 ± 10.4 | 881.0 ± 162.5† |
| Inhibition ratio (Q/I) | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.4 ± 0.04 | 0.9 ± 0.1† |
| Contractions/PCC | 24.1 ± 5.7 | 17.0 ± 7.4 | 18.3 ± 1.5 | 4.1 ± 2.2† |
| Speed (mm s−1) | 1.9 ± 0.4 | 1.1 ± 0.4 | 2.3 ± 1.0 | 0.1 ± 0.1 |
| Velocity (mm s−1) | 0.2 ± 0.5 | −0.5 ± 0.5 | −1.9 ± 1.0 | −0.1 ± 0.1 |
Paired t test between treatments:
*
P < 0.05;
†
P < 0.01.